

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112
<b>Information Disclosure Statement by Applicant (Use several sheets if necessary)</b>  (37 CFR §1.98(b))		Applicant Jeffrey S. Ross		
		Filing Date December 15, 2003	Group Art Unit 1642	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
/T.D./	AC	WO 02/09885	Dec. 12, 2002	WIPO			
	AD						
	AE						

Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
/T.D./	AF	Copy of EP Search Report dated Feb. 22, 2007					
	AG	Okegawa et al. "Value of Reverse Transcription Polymerase Chain Reaction Assay in Pathological Stage T3N0 Prostate Cancer", <u>The Prostate</u> , Vol. 44, no. 3: pages 210-218 (2000)					
	AH	Chang et al. "The clinical role of prostate-specific membrane antigen (PSMA)", <u>Urologic Oncology</u> , Vol. 7, no. 1: pages 7-12 (2002)					
↓	AI	Okegawa et al., "DETECTION OF MICROMETASTATIC PROSTATE CANCER CELLS IN THE LYMPH NODES BY REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION IS PREDICTIVE OF BIOCHEMICAL RECURRENCE IN PATHOLOGICAL STAGE T2 PROSTATE CANCER", <u>The Journal of Urology</u> , Vol. 163, no. 4: pages 1183-1188 (2000)					
	AJ						

Examiner Signature /Minh Tam Davis/ (09/02/2007)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	